AUG 15, 2019 6:26 AM PDT

Drug Targets Early Instigators of Alzheimer Disease

WRITTEN BY: Nouran Amin

The two solidifying instigators of Alzheimer -disease (AD)—amyloid beta and the tau protein—have long been the topic of study for AD researchers. Amyloid beta contributes to AD by solidifying into toxic plaques that accumulate in the extracellular spaces of nerve tissue and the tau protein will tangle in the bodies of neurons affecting their function. These plaques and tangles are the hallmarks of AD and as a result studies are always looking for initiating drug development that targets these hallmarks.

Learn more on Alzheimer Disease:

Previous studies involving therapeutic development for AD specifically for targeting the hallmarks has often faced failure and the challenge to reverse cognitive decline as result of the disease remains at the forefront of research. Now, at the Arizona Center for Drug Discovery based at the UA College of Pharmacy, researchers have examined a molecule drug called ‘DYR219’ as a possible therapeutic for AD. DYR219 is believed to be unique in its ability to not target the hallmarks of AD but instead acts on the pathways that leads to these hallmarks. In other words, the drug acts as a prevention instead of a treatment.

“If you can block that process early, you can delay the downstream aggregation and formation of the pathologies,” says Travis Dunckley, a researcher at the ASU-Banner Neurodegenerative Disease Research Center.

Findings of the study were published in the journal Molecular Neurobiology and describes how the inhibitive effects of DYR219, or a similar drug, can eventually place a stop to AD development. By preventing or delaying the development of AD pathologies, DYR219 or a similar drug may halt the progression of Alzheimer’s in its tracks, before it damages the brain beyond repair.

“We showed a robust and significant delay in the onset of amyloid and tau pathology,” Dunckley says. “The reason I’m excited about this, especially in the face of a lot of the recent high profile clinical trial failures, is that this is really a different approach to treating the disease.”

Essentially, the drug works as a preventive measure by inhibiting a particular neuroactive enzyme called DYRK1 that holds crucial role in plaque and tangle formation in AD.

DYR219 is a powerful new drug developed to inhibit a kinase known as DYRK1. The inhibition targets leading pathologies of with Alzheimer's disease—plaques, (caused by the protein amyloid beta) and tangles, (caused by the tau protein). The drug can open new doors to preventing cognitive decline. Credit: Arizona State University, Graphic by Shireen Dooling

Source: Biodesign @ Arizona State University

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
SEP 17, 2021
Cell & Molecular Biology
How Stem Cells May Aid in the Treatment of MRSA
SEP 17, 2021
How Stem Cells May Aid in the Treatment of MRSA
MRSA (methicillin-resistant Staphylococcus aureus) is a well known superbug, a pathogenic microbe that can cause serious ...
OCT 09, 2021
Cell & Molecular Biology
The Anti-Cancer, Copper-Binding Compounds Found in Fish
OCT 09, 2021
The Anti-Cancer, Copper-Binding Compounds Found in Fish
In the world's waterways, fish are confronted with endless challenges. For example, they have to defend themselves from ...
OCT 18, 2021
Health & Medicine
Emerging Research on Delta 8 THC
OCT 18, 2021
Emerging Research on Delta 8 THC
Delta-8-tetrahydrocannabinol is a cannabinoid derived from the hemp plant. It is one of the more prominent compounds, bu ...
OCT 24, 2021
Microbiology
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
OCT 24, 2021
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
Bacteria can be found almost everywhere, and they can serve many beneficial purposes. Scientists are now using bacterial ...
OCT 29, 2021
Health & Medicine
The Happenstance Discovery of Delta 10 THC
OCT 29, 2021
The Happenstance Discovery of Delta 10 THC
The random discovery of Delta 10 is a good example of how cannabis science has only just begun to explore the complexity ...
NOV 08, 2021
Drug Discovery & Development
A case study of CBD's tumor shrinking potential
NOV 08, 2021
A case study of CBD's tumor shrinking potential
A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. ...
Loading Comments...